The pricing cycle is over; volume must lead
The structural shift that defined global dairy through 2024 is now the dominant commercial reality in the Netherlands. For three years, dairy brands ran top-line growth on price increases. That route is closing. Danone, the category's most prominent multinational player with significant Dutch operations, reported FY 2025 global sales of €27.3 billion, up 4.5% on a like-for-like basis. The detail that matters for Dutch commercial planners: volume and mix contributed +2.7 percentage points while pricing added only +1.8, the first time since 2022 that volume has outpaced pricing. A category that grew on price does not need deep brand investment to hit a number. A category that must grow on volume does. That is the environment Dutch dairy leaders are now managing.
The implication is straightforward: promotional discipline, pack architecture, and channel execution matter more than they did 18 months ago. Any brand that coasted on list-price carry will face a harder Q2 and a harder H2 beyond it.
The cereulide incident and what it means for Dutch supply chains
The Netherlands sits at the centre of a live and unresolved food safety episode. A joint investigation by Radio France, Belgian broadcaster RTBF, and Switzerland's RTS alleged that cereulide toxin was detected in samples at a Dutch factory toward the end of November 2025, but markets including France, Belgium, and Switzerland were not officially informed until January 5. The broadcasters also alleged that quiet recalls in Austria and Germany began on December 24, before any public announcement. Nestlé has pushed back hard, calling the broadcaster reports "inaccurate and misleading." The dispute remains live.
For Dutch dairy category managers, this matters beyond the companies named. Infant formula and specialised nutrition are high-scrutiny segments where a single safety event can reshape retailer ranging decisions and consumer trust for a full shelf cycle. The fact that the alleged detection site is a Dutch facility means that Dutch regulators, logistics partners, and retail buyers will be watching for the official resolution of this case with particular attention. How quickly and transparently the full chain of events is accounted for will shape category trust in the Netherlands into H2 2026.
Danone's exposure runs in parallel. Per the CT-series company topics, Danone was among the manufacturers caught in the same cereulide contamination event, which triggered product recalls across nearly 100 countries. Danone's specialised nutrition business is strategically core to its long-term growth model, and any lasting consumer hesitation in that segment would arrive at exactly the moment the company needs volume to compensate for fading pricing power.
RTD dairy and functional formats: the most credible growth lane
Across western Europe, the ready-to-drink dairy beverage format is gaining commercial traction fastest among brands that combine convenience with a clear functional claim. The global RTD beverage market is on track to reach nearly $1.5 trillion by the mid-2030s, up roughly 67% from 2026, according to Fortune Business Insights data cited in trade coverage. Danone has leaned into this format, launching Oikos Fusion as an RTD nutritional shake and entering the ambient protein shakes space through an Oikos-branded range in the US. The direction of travel is clear: dairy brands are using RTD as the vehicle to reach consumers who want protein and gut health support in a portable, shelf-stable format.
The gut health trend sits directly beneath this. A GlobalData survey found that 42% of global consumers say gut health is an outcome they are actively trying to improve, with Gen Z and Millennial figures reaching 40% and 45% respectively. In the Netherlands, a market with high nutritional literacy and strong retailer engagement on health positioning, this consumer current is a real commercial lever for brands with credible probiotic or prebiotic credentials. Yogurt, kefir, and fortified dairy beverages are all well-placed to capture spending that would otherwise flow to supplement or functional beverage categories.
Protein: from differentiator to baseline
Protein has made the same journey in dairy that it has made across snacks, bread, and pasta: from premium claim to category baseline. As one industry commentator put it, early on simply adding protein was enough to stand out; that is no longer the case. Dutch dairy brands that entered the protein segment two to three years ago and have not evolved their offer since may find that claim is no longer moving units. The new battleground is protein source, completeness, and satiety relevance, particularly for consumers on GLP-1 medications, who are growing in number and who prioritise protein intake while managing weight.
Dairy-derived proteins, including casein and whey, are the natural beneficiaries of this shift if brands can build the right claim architecture. But whey protein prices have surged significantly since January (as flagged in the X2 and X3 prior outlooks), creating a margin squeeze for manufacturers who rely on dairy-derived protein as an ingredient in reformulated or fortified lines. Managing that ingredient cost while maintaining a competitive retail price will be one of the tighter commercial challenges in Q2.
Danone exits Lifeway: reading the portfolio signal
In May, Danone confirmed it is selling its 22.7% stake in Lifeway Foods via a secondary offering priced at $19.50 per share, closing out a relationship that began in 1999. Danone made two acquisition bids for Lifeway in 2024, at $25 and $27 per share, both rejected. The sale is a clean signal: Danone is not willing to overpay for kefir exposure in North America and will redirect capital elsewhere. For Dutch and European commercial observers, the implication is that Danone's portfolio attention is narrowing toward core dairy and plant-based lines where it has scale and margin control, rather than expanding into minority stakes in adjacent fermented dairy businesses. That focus should, in theory, benefit its European retail relationships. But it also means that any growth gaps Danone leaves in fermented or functional dairy sub-segments in the Netherlands could be a genuine ranging opportunity for regional or private label alternatives.
Ice cream M&A: Magnum and the private equity watch
The Magnum Ice Cream Company, spun off by Unilever in late 2024 and still 19.9% owned by Unilever, is attracting early-stage private equity attention. Blackstone and CD&R are both reportedly in early stages of exploring bids, with both firms tracking share price and summer sales before committing. The Netherlands is Magnum's home market in a cultural and historical sense, and the brand's performance over Q2 and Q3 in Dutch retail and foodservice will almost certainly be part of any due diligence on a bid.
For Dutch retail buyers and category managers, a private equity acquisition of Magnum would likely accelerate trade investment and promotional activity in the short term as new owners seek to demonstrate growth momentum. Watch for any shift in promotional frequency or shelf-space negotiation posture from Magnum's commercial team as the summer season progresses and bid interest becomes clearer.
Ingredient costs and commodity exposure
Geopolitical pressures continue to push up input costs across the dairy supply chain. West Asia conflict dynamics have elevated crude-linked packaging costs, freight rates, and commodity prices broadly. In India, Amul and Mother Dairy raised milk prices by 2 rupees per litre on 15 May, a signal of global dairy commodity cost direction even if the Dutch market operates under different farmgate dynamics. Dutch dairy processors, many of whom export significant volumes of cheese, butter, and milk powder, are exposed to the same global commodity pricing environment.
The fibre reformulation trend adds another layer of ingredient complexity. Trade coverage notes that different fibres have vastly different functional properties, and a fibre that works in a beverage may fail entirely in a dairy or bakery application. For Dutch dairy brands trying to build gut health credentials by adding prebiotic fibres to yogurt or drinking dairy, the formulation challenge is real and not trivial to solve at speed.
What buyers and category leaders should watch
Four things deserve close attention going into the rest of Q2 and the start of H2. First, the resolution of the cereulide contamination dispute. Whether regulators and retailers conclude that disclosure timelines were appropriate or not will shape infant formula and specialised nutrition ranging decisions across Dutch retail for the remainder of the year. Second, Danone's volume trajectory in European dairy. FY 2025 showed volume finally leading, but sustaining that through an environment of cost pressure and consumer caution is not guaranteed. Third, Magnum summer sales. The ice cream brand's Q2 commercial performance will be watched not just by retail buyers but by private equity firms deciding whether to bid. And fourth, protein ingredient costs. Any further acceleration in whey prices will compress margins on the fastest-growing segment of Dutch functional dairy, and brands with fixed promotional commitments and rising ingredient bills will face difficult choices on pack size, retail price, or promotional depth.